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INTRODUCTION
Maternal chorioamnionitis has been known to result in a
lung maturation response. The incidence of respiratory dis-
tress syndrome in preterm infants decreased when they were
exposed to maternal chorioamnionitis (1). In animal study,
maternal chorioamnionitis increased the size of surfactant
pool and the volume of potential gas space (2). However,
maternal chorioamnionitis has also been associated with ab-
normal lung development. The exposure to maternal cho-
rioamnionitis increased the incidence of bronchopulmonary
dysplasia (BPD) in preterm infants (1, 3), and resulted in
alveolar simplification and impaired microvascular develop-
ment (4, 5), which are histologic hallmarks of new BPD in
the post-surfactant era (6).
Transforming growth factor-beta (TGF-β ) is an impor-
tant regulator of cellular proliferation and differentiation. It
has been considered to be crucial for the normal lung devel-
opment and implicated in the development of BPD. Dur-
ing branching morphogenesis in the lung development, the
expression of TGF-βwas reduced (7, 8). Overexpression of
TGF-βinhibited airway branching (8, 9), while inhibition
of TGF-βenhanced airway branching in vitro (9-11). Com-
pared to branching morphogenesis, neither the role nor the
status of expression of TGF-βduring alveolarization is well
known. Several researchers reported that overexpression of
TGF-β 1 inhibited alveolarization in neonatal rat (12, 13),
and inhibition of TGF-βresulted in an emphysematous change
in adult mouse (14, 15). However, the role of TGF-βin nor-
mal lung development, especially during alveolarization in
human preterm infants, remains unclear.
TGF-βis also known as an important mediator of fibro-
sis. Kotecha et al. reported an increased level of TGF-β 1i n
bronchoalveolar lavage (BAL) fluid of preterm infants who
developed BPD later (16). In animal model, enhanced endoge-
nous production or overexpression of TGF-β 1 resulted in
pulmonary pathologic changes seen in human BPD, which
are enlarged alveolar sacs, poor secondary septation, thick
and hypercellular septa, and abnormal capillary development
(12, 13, 17). However, the role of TGF-βin the injury response
of the lungs in preterm infants also remains unclear.
The objective of our study was to examine the effect of
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Decreased Expression of Transforming Growth Factor-beta1 in 
Bronchoalveolar Lavage Cells of Preterm Infants with Maternal
Chorioamnionitis
Maternal chorioamnionitis has been associated with abnormal lung development.
We examined the effect of maternal chorioamnionitis on the expression of trans-
forming growth factor-beta1 (TGF-β β 1) in the lungs of preterm infants. A total of 63
preterm (≤ ≤34 weeks) infants who were intubated in the delivery room were prospec-
tively enrolled. Their placentas were examined for the presence of chorioamnioni-
tis. Bronchoalveolar lavage (BAL) fluid and cells were obtained shortly after birth.
TGF-β β 1 was measured in BAL fluid and TGF-β β 1 mRNA expression was determined
by reverse transcription polymerase chain reaction (RT-PCR) in BAL cells. TGF-β β 1
mRNA expression in BAL cells showed a positive correlation with gestational age
(r=0.414, p=0.002). TGF-β β 1 mRNA expression was significantly decreased in the
presence of maternal chorioamnionitis (0.70± ±0.12 vs. 0.81± ±0.15, p=0.007). Adjust-
ment for gestational age, birth weight, and delivery mode did not nullify the signifi-
cance. TGF-β β 1 mRNA expression was marginally significantly decreased in preterm
infants who developed bronchopulmonary dysplasia (BPD) later (0.75± ±0.11 vs.
0.82± ±0.15, p=0.055). However, adjustment for gestational age, patent ductus
arteriosus (PDA), and maternal chorioamnionitis nullified the significance. These
results might be an indirect evidence that maternal chorioamnionitis may inhibit
normal lung development of fetus.
Key Words : Transforming Growth Factor-beta; Chorioamnionitis; Bronchopulmonary Dysplasia
Received : 10 July 2007
Accepted : 15 December 2007610 C.W. Choi, B.I. Kim, K.E. Joung, et al.
maternal chorioamnionitis on the expression of TGF-β 1, the
isoform most implicated in fibrosis among its three isoforms
whose biological properties are nearly identical, and com-
pare the extent of TGF-β 1 expression between preterm infants
who develop BPD later and who do not.
MATERIALS AND METHODS
Study design
A prospective cohort study was done to examine the effect
of maternal chorioamnionitis on the expression of TGF-β 1i n
BAL cells of preterm infants. The cohort consisted of preterm
(gestational age <34 weeks) infants who were admitted to
neonatal intensive care unit (NICU) at Seoul National Uni-
versity Children’s Hospital and Seoul National University
Bundang Hospital (after May 2003) between March 1999
and February 2004 and who met the following criteria: 1)
endotracheal intubation at delivery room, and 2) absence of
major congenital anomalies. During the study period, a total
of 79 preterm infants were enrolled. Among these preterm
infants, 7 infants whose parents’ consent was not obtained
and 9 infants to whom BAL was not done or done after the
first 24 hr after birth due to death or clinical instability were
excluded from the analysis. Finally 63 preterm infants were
analyzed. Of these, 8 preterm infants died before 36 weeks
postmenstrual age when the assessment for the development
of BPD was made. The institutional review board at Seoul
National University Hospital approved the study protocol
(H-0603-230-172), and informed consent was obtained
from a parent before enrollment. 
Bronchoalveolar lavage
Endotracheal intubation in the delivery room was done
only when clinically indicated according to the neonatal
resuscitation program (18). BAL fluid and cells were obtain-
ed by the method described by Kotecha (19) shortly after
birth as soon as the preterm infants became stable, but before
surfactant replacement therapy when indicated. Briefly, with
the baby supine, two aliquots of sterile saline solution, 1 mL/
kg (maximum 2 mL), were instilled via endotracheal tube,
and then immediately sucked back, and the returned BAL
fluid was collected in a suction trap. BAL fluid was centrifug-
ed for 10 min at 1,000 g within 10 min after acquisition. The
supernatant and sediment, which is a cell fraction, were con-
tained to separate polypropylene tubes, and stored at -70℃
and -160℃in liquid nitrogen, respectively. The stored super-
natant and sediment were used for the measurement of TGF-
β 1 concentration and TGF-β 1 mRNA reverse transcription
polymerase chain reaction (RT-PCR), respectively.
Determination of TGF-β β 1 and TGF-β β 1 mRNA in BAL
fluid and cells
The TGF-β 1 concentration in BAL fluid was measured
using a commercially available ELISA kit (Quantikine
� human
TGF-β 1 immunoassay, R&D Systems Inc., Minneapolis, MN,
U.S.A.). The sensitivity of the test was <7 pg/mL. Interas-
say and intra-assay coefficients of variation were 7.3% and
11.7%, respectively. The frozen BAL fluid sediment in liq-
uid nitrogen was pulverized and homogenized using Qia-
shredder
� (Quiagen Inc., Valencia, CA, U.S.A.). The extrac-
tion of mRNA from the homogenates was done using Olig-
otex
� direct mRNA kit (Quiagen Inc.). Reverse transcription
of TGF-β 1 mRNA was done using MuLV reverse transcrip-
tase (PerkinElmer Inc., Waltham, MA, U.S.A.) and RNA
PCR kit
� (PerkinElmer Inc.). The sense and antisence primers
for human TGF-β 1 cDNA were designed by PrimerSelect
�
version 3.11 (DNAStar Inc., Madison, WI, U.S.A.). The
primer for forward reaction was 5′ GCCCTGGATACCAA-
CTATTGCT3′ , and the primer for reverse reaction was 5′
AGGCTCCAAATATAGGGGCAGG3′ . PCR was done
using automatic PCR cycler (Gene Cycler
�, Bio-Rad Labo-
ratories, Hercules, CA, U.S.A.). The size of the PCR prod-
uct was 161 bp. For internal standard, PCR was also done
for β -actin. PCR products were loaded and analyzed on 1%
agarose gel with a 10-fold diluted 100 bp DNA ladder (Pro-
mega Corp. Madison, WI, U.S.A.) as a DNA marker. Image
analysis was performed using ‘Band leader’ software version
2.01. The signal intensity of TGF-β 1 mRNA was expressed
relative to that of β -actin. 
Definition of maternal chorioamnionitis and bronchopul-
monary dysplasia
Maternal chorioamnionitis was defined histologically as
≥grade 2 inflammation of the amnion or choriodecidua or
≥grade 1 necrotizing funisitis according to the grading sys-
tem suggested by Salafia et al. (20). BPD was defined as a
state of chronic oxygen requirement at 36 weeks postmen-
strual age plus a total oxygen duration of ≥28 day with a
consistent chest radiographic finding, which is persistent
hazy opacification or a cyst-like pattern of density and lucency. 
Statistical analysis
Statistical analysis was done using SPSS version 11.5 (SPSS
Inc., Chicago, IL, U.S.A.). Comparison of means between
groups was performed using one-way analysis of variance
(ANOVA) test or Mann-Whitney U-test. Comparison of fre-
quencies between groups was done using 
2 or Fisher’s exact
test. To investigate the relationship between TGF-β 1 or TGF-
β 1 mRNA in BAL fluid and cells and maternal chorioam-
nionitis or BPD, while eliminating the effects of potential
confounding variables, multivariate logistic regression anal-Transforming Growth Factor-beta1 and Maternal Chorioamnionitis 611
ysis was performed. A p value of <0.05 was considered sta-
tistically significant.
RESULTS
Clinical profiles of preterm infants with and without mater-
nal chorioamnionitis
Gestational age and the rate of Cesarean section delivery
were significantly lower in preterm infants with maternal
chorioamnionitis. There were no significant differences in
birth weight, Apgar scores at 1 and 5 min, sex ratio, prema-
ture rupture of membrane, antenatal steroid therapy, and
intrauterine growth restriction. Respiratory distress syndrome
(RDS) was significantly less prevalent, while BPD was more
Maternal 
chorioamnioni-
tis (n=23)
No maternal
chorioamnioni-
tis (n=40)
p
Birth weight (g) 1,096±418 1,328±514 0.070
Gestational age (week) 27.6±3.0 30.1±2.6 <0.001
Apgar score at 1 min 4.0±2.4 4.3±2.4 0.748
Apgar score at 5 min 5.7±2.2 5.8±2.5 0.845
Male (%) 14 (61) 17 (43) 0.196
Cesarean section (%) 13 (57) 38 (95) <0.001
PROM (%) 8 (35) 7 (18) 0.137
Antenatal steroid (%) 17 (74) 20 (50) 0.110
IUGR (%) 1 (4) 6 (15) 0.407
RDS (%) 11 (48) 31 (78) 0.026
PDA (%) 14 (61) 24 (60) 1.000
BPD (%) 16 (70) 15 (38) 0.019
Sepsis (%) 4 (17) 9 (23) 0.753
PVL (%) 1 (4) 1 (3) 1.000
TGF-β 1 in BAL fluid (pg/mL) 85.5±49.1 87.1±67.2 0.925
TGF-β 1 mRNA in BAL cells  0.70±0.12 0.81±0.15 0.007
(relative to β -actin)
Table 1. Clinical profiles, TGF-β 1 in BAL fluid and TGF-β 1 mRNA
in BAL cells of preterm infants with and without maternal chori-
oamnionitis
Data shown as mean±SD.
TGF-β 1, transforming growth factor-beta1; BAL, bronchoalveolar lavage;
PROM, premature rupture of membrane; IUGR, intrauterine growth
restriction; RDS, respiratory distress syndrome; PDA, patent ductus
arteriosus; BPD, bronchopulmonary dysplasia; PVL, periventricular leuko-
malacia.
Adjusted odds ratio for
maternal chorioamnionitis
(95% confidence interval)
p
TGF-β 1 mRNA in BAL cells  0.038 1.8 (1.0-3.3)
(relative to β -actin)
(per 0.1 decrease)
Birth weight  0.076 1.3 (0.9-2.0)
(per 100 g decrease)
Gestational age 0.015 1.9 (1.1-3.2)
(per 1 week decrease)
Vaginal delivery (over  0.018 13 (1.5-103)
Cesarean section delivery)
Table 2. Adjusted odds ratio of each significant variable for the
presence of maternal chorioamnionitis assessed by logistic
regression analysis
TGF-β 1, transforming growth factor-beta1; BAL, bronchoalveolar lavage.
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Fig. 1. The correlations between TGF-β 1 mRNA in BAL cells and gestational age (A) and birth weight (B). (A) A significant positive corre-
lation is shown in total population (r=0.414, p=0.002) and in the subgroup without maternal chorioamnionitis (r=0.412, p=0.014), while
poor correlation in the subgroup with maternal chorioamnionitis. (B) A significant positive correlation is shown in total population (r=0.372,
p=0.005) and in the subgroup without maternal chorioamnionitis (r=0.481, p=0.003), while poor correlation in the subgroup with maternal
chorioamnionitis.
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prevalent in preterm infants with maternal chorioamnioni-
tis. There were no significant differences in echocardiogra-
phy-documented patent ductus arteriosus, culture-proven
sepsis, and periventricular leukomalacia (Table 1). 
TGF-β β 1 and TGF-β β 1 mRNA in BAL fluid and cells in pre-
term infants with and without maternal chorioamnionitis
The concentrations of TGF-β 1 in BAL fluid were lower in
preterm infants with maternal chorioamnionitis, although
statistically insignificant. Signal intensities of TGF-β 1 mRNA
expressed relative to that of β -actin were significantly lower
in preterm infants with maternal chorioamnionitis (0.70±
0.12 vs. 0.81±0.15, p=0.007) (Table 1).
Multivariate logistic regression analysis including con-
founders such as birth weight, gestational age and Cesarean
section delivery in the logistic model revealed an indepen-
dent relationship between TGF-β 1 mRNA in BAL cells and
maternal chorioamnionitis (adjusted odds ratio 1.8 per 0.1
decrease of signal intensity of TGF-β 1 mRNA expressed rela-
tive to that of β -actin, 95% confidence interval 1.0-3.3)
(Table 2).
The correlations between TGF-β β 1 mRNA in BAL cells
and gestational age and birth weight
Signal intensity of TGF-β 1 mRNA expressed relative to
β -actin demonstrated a moderate positive correlation with
gestational age (r=0.414, p=0.002) and birth weight (r=
0.372, p=0.005). However, in preterm infants with mater-
nal chorioamnionitis, there were no correlations between
them. In preterm infants without maternal chorioamnioni-
tis, there were also moderate correlations between signal
intensity of TGF-β 1 mRNA and birth weight and gesta-
tional age (Fig. 1).
There were no correlations between the concentration of
TGF-β 1 in BAL fluid and birth weight or gestational age
(data not shown).
Clinical profiles of preterm infants who developed BPD
and who did not
Birth weight, gestational age, and Apgar scores at 1 and 5
min were significantly lower in preterm infants who devel-
oped BPD later. Maternal chorioamnionitis, echocardiogra-
phy-documented patent ductus arteriosus (PDA) and cul-
ture-proven sepsis were more prevalent in preterm infants
who developed BPD later. The higher prevalence of sepsis
in preterm infants who developed BPD later was thought
BPD
(n=28)
No BPD
(n=27)
p
Birth weight (g) 997±235 1,649±397 <0.001
Gestational age (week) 28.1±2.3 31.8±1.9 <0.001
Apgar score at 1 min 3.7±2.0 5.3±2.4 0.007
Apgar score at 5 min 5.3±1.7 6.8±2.3 0.009
Male (%) 15 (54) 13 (48) 0.688
Cesarean section (%) 23 (82) 22 (82) 0.949
Maternal chorioamnionitis (%) 15 (54) 5 (19) 0.007
PROM (%) 6 (21) 6 (22) 0.943
Antenatal steroid (%) 19 (68) 13 (48) 0.139
IUGR (%) 3 (11) 2 (7) 0.670
RDS (%) 17 (61) 20 (74) 0.291
PDA (%) 24 (86) 12 (44) 0.001
Sepsis (%) 11 (39) 0 (0) <0.001
PVL (%) 2 (7) 0 (0) 0.157
TGF-β 1 in BAL fluid (pg/mL) 89.9±71.9 91.4±55.1 0.936
TGF-β 1 mRNA in BAL cells  0.75±0.11 0.82±0.15 0.055
(relative to β -actin)
Table 3. Clinical profiles, TGF-β 1 in BAL fluid and TGF-β 1 mRNA
in BAL cells of preterm infants who developed bronchopul-
monary dysplasia later and who did not
Data shown as mean±SD.
Eight preterm infants died before 36 weeks postmenstrual age when
the assessment for the development of BPD was made and were exclud-
ed from the analysis.
TGF-β 1, transforming growth factor-beta1; BAL, bronchoalveolar lavage;
PROM, premature rupture of membrane; IUGR, intrauterine growth
restriction; RDS, respiratory distress syndrome; PDA, patent ductus
arteriosus; BPD, bronchopulmonary dysplasia; PVL, periventricular
leukomalacia.
MCA (n=20)
BPD
(n=15)
No BPD
(n=5)
No MCA (n=35)
BPD
(n=13)
No BPD
(n=22)
TGF-β 1 in BAL  83.8±47.4 137.7±70.3 96.4±93.1 86.9±53.4
fluid (pg/mL)
p 0.171 0.709
TGF-β 1 mRNA in  0.71±0.12 0.66±0.16 0.79±0.10 0.86±0.13
BAL cells 
(relative to β -actin)
p 0.496 0.097
BPD (n=28)
MCA
(n=15)
No MCA
(n=13)
No BPD (n=27)
MCA
(n=5)
No MCA
(n=22)
TGF-β 1 in BAL  83.8±47.4 96.4±93.1 137.7±70.3 86.9±53.4
fluid (pg/mL)
p 0.659 0.221
TGF-β 1 mRNA in  0.71±0.12 0.79±0.10 0.66±0.16 0.86±0.13
BAL cells 
(relative to β -actin)
p 0.106 0.007
Table 4. TGF-β 1 in BAL fluid and TGF-β 1 mRNA in BAL cells by
the presence of maternal chorioamnionitis and the development
of bronchopulmonary dysplasia
Data shown as mean±SD.
TGF-β 1, transforming growth factor-beta1; BAL, bronchoalveolar lavage;
MCA, maternal chorioamnionitis; BPD, bronchopulmonary dysplasia.Transforming Growth Factor-beta1 and Maternal Chorioamnionitis 613
to be consequential rather than causative of BPD consider-
ing the temporal relationship between them. There were no
significant differences in sex ratio, the rate of Cesarean sec-
tion delivery, premature rupture of membrane, antenatal
steroid therapy, intrauterine growth restriction, RDS and
periventricular leukomalacia (Table 3).
TGF-β β 1 and TGF-β β 1 mRNA in BAL fluid and cells and
later development of BPD
The concentrations of TGF-β 1 in BAL fluid did not differ
significantly between preterm infants who developed BPD
later and who did not (Table 3). Signal intensities of TGF-β 1
mRNA expressed relative to β -actin in BAL cells were mar-
ginally significantly lower in preterm infants who developed
BPD later (0.75±0.11 vs. 0.82±0.15, p=0.055) (Table 3). 
Subsequent subgroup analyses by the presence of mater-
nal chorioamnionitis and the development of BPD demon-
strated no significant differences in the concentration of TGF-
β 1 in BAL fluid and signal intensities of TGF-β 1 mRNA
expressed relative to β -actin in BAL cells, except for preterm
infants who did not develop BPD (Table 4). Multivariate
logistic regression analysis including confounders such as
gestational age, chorioamnionitis and PDA which were sig-
nificant variables in the univariate analysis in the logistic
model failed to reveal an independent relationship between
TGF-β 1 mRNA in BAL cells and the later development of
BPD (Table 5).
DISCUSSION
Pulmonary fibrosis was a prominent feature in preterm
infants who died of BPD (21, 22). Moreover, markers of fibro-
sis such as hydroxyproline, fibronectin, and desmosine were
increased in lung tissue, tracheal fluid, and urine of preterm
infants who developed BPD (23-25). TGF-βhas been known
to be an important mediator of fibrosis. Accordingly, TGF-
βhas been implicated in the pathogenesis of BPD. Kotecha
et al. (16) demonstrated increased levels of TGF-β 1 in BAL
fluid in preterm infants who developed BPD later. Howev-
er, as with the introduction of antenatal steroid, surfactant
replacement therapy, and gentle ventilatory strategies, the
incidence of classic BPD in which fibrosis is a predominant
feature has decreased (26). Instead, a milder new type of BPD
has been increasing in preterm infants who were not exposed
to significant hyperoxia and baro/volutrauma (27). This type
of BPD in the post-surfactant era has different pathologic
characteristics from that of classic BPD. It lacks fibrosis, air-
way injury, and emphysema which are predominant features
of classic BPD. Instead, an arrest in alveolar and microvas-
cular development is the pathologic hallmark of this type of
BPD in the post-surfactant era (6).
Recently, there has been growing evidence that antenatal
inflammatory process may inhibit normal alveolarization (4,
5, 28). In epidemiologic and clinical studies, antenatal inflam-
mation or maternal chorioamnionitis was related to the devel-
opment of BPD (1, 29-31). However, there have been few
studies as to the status of TGF-βexpression in the lungs
when the fetus is exposed to maternal chorioamnionitis. The
exact role of TGF-βin normal alveolarization phase in human
lung development is not known clearly, although its role in
branching morphogenesis is well known in in-vitro studies
(7-11). Considering that an increased TGF-βlevel has been
associated with the development of BPD, it could be reason-
ably postulated that TGF-βwould be increased in preterm
infants with maternal chorioamnionitis which has also been
related to the development of BPD. Recently, Kunzmann et
al. (32), demonstrated elevated TGF-β 1 mRNA and protein
expression in the lungs by experimental maternal chorioam-
nionitis in preterm neonatal sheep model. In contrast, the
expression of connective tissue growth factor, a down-stream
mediator of some of the pro-fibrotic effects of TGF-β 1, decreas-
ed. In our study, however, the expression of TGF-β 1 mRNA
and protein decreased in BAL cells and fluid obtained short-
ly after birth from the preterm infants who were exposed to
maternal chorioamnionitis, although the latter lacked sta-
tistical significance. These results are opposing to those of
Kunzmann et al. and also to common expectation. Some
speculations may be done as to our unexpected results. Firstly,
in our study, the profile of BAL cells was not analyzed. There-
fore, decreased expression of TGF-β 1 mRNA could be sim-
ply a reflection of different cell profiles. If the proportion of
cell types in BAL fluid obtained from each preterm infant
differed by the presence of airway inflammation or maturity,
the interpretation of the measured value of a specific mRNA
which is expressed differently by airway cell type would be
problematic. In our study, there is a possibility that the pro-
portion of three major cell types of BAL cell which are alve-
olar macrophages, neutrophils, and epithelial cells may be
affected by maternal chorioamnionitis and gestational age.
Adjusted odds ratio for
BPD
(95% confidence interval)
p
TGF-β 1 mRNA in BAL cells  0.486 1.3 (0.6-3.1)
(relative to β -actin)
(per 0.1 decrease)
Gestational age 0.002 3.3 (1.6-7.0)
(per 1 week decrease)
Maternal chorioamnionitis 0.385 2.8 (0.3-28)
PDA 0.011 33 (2.2-502)
Table 5. Adjusted odds ratio of each significant variable for the
development of bronchopulmonary dysplasia assessed by
logistic regression analysis
BPD, bronchopulmonary dysplasia; BAL, bronchoalveolar lavage; PDA,
patent ductus arteriosus.614 C.W. Choi, B.I. Kim, K.E. Joung, et al.
However, TGF-β 1 is known to be markedly expressed in
alveolar macrophages, and to a lesser degree, in neutrophils
and epithelial cells (16). If it is the case, the validity of TGF-
β 1 mRNA value in BAL cells by RT-PCR method would be
unaffected. Secondly, the method of BAL can matter. We
used non-bronchoscopic BAL due to infeasibility of bron-
choscopy for study preterm infants because of their small
body size. Therefore, there may be a concern that the cells
from distal airway and alveoli were not obtained sufficient-
ly. However, Kotecha (33) reported that the cell profiles of
non-bronchoscopic BAL cells from each lung were very sim-
ilar, thus very representative of lung environment. Grigg et
al. (34) also demonstrated that a sufficient amount of distal
airway cells was obtained by non-bronchoscopic BAL. There-
fore, decreased expression of TGF-β 1 mRNA in non-bron-
choscopic BAL cells in our study may be thought to be rep-
resentative of actual alveolar environment. However, further
studies that will analyze the cell profiles of BAL cells are
required to eradicate the controversy on the representative-
ness of true alveolar environment of our data. Moreover, the
lack of statistical significance of TGF-β 1 in BAL fluid in com-
parison to that of its m-RNA expression in BAL cell was
observed in our study. This disparity between TGF-β 1 m-
RNA and its protein was not observed in other recent study
that dealt with the same molecule and might have originat-
ed from the small sample size and/or post-transcriptional
modifications (32). However, its elucidation requires further
studies.
In this study, the expression of TGF-β 1 in BAL cells show-
ed a significant positive correlation with gestational age and
birth weight. It increased as gestational age and birth weight
increased. When maternal chorioamnionitis was present, the
expression of TGF-β 1 in BAL cells significantly decreased inde-
pendently of gestational age and birth weight. If our data
are acceptable as a reflection of actual alveolar environment,
it could be suggested that the expression of TGF-β 1 in the
lungs increases as a function of maturity, and that maternal
chorioamnionitis exerts a negative influence on this normal
increase of TGF-β 1 expression at the later phase of human lung
development. These findings may be thought to be an indi-
rect evidence showing the possibility that maternal chorioam-
nionitis might inhibit normal lung development of fetus,
although the exact role and the expression status of TGF-β 1
in saccular phase are not known clearly. Be that as it may be,
however, this assumption is not supported by our results in
that there was no significant relationship between the expres-
sion of TGF-β 1 in BAL cells and the development of BPD.
There should be another caution in interpreting our results.
The study subjects in our study were preterm infants who
needed tracheal intubation in delivery room. However, they
were relatively larger preterm infants with a mean birth weight
of 1,243±491 g and a gestational age of 29.5±3.1 weeks
who can usually be managed successfully without intubation
in delivery room nowadays. Therefore, there is a possibility
that the preterm infants enrolled to our study might have
suffered some antenatal insults such as maternal chorioam-
nionitis and perinatal asphyxia. Actually, the incidence of
maternal chorioamnionitis is as high as 37% and the 5-min
Apgar score was as low as 5±2, each of which is higher and
lower than 27% and 7±2, respectively, of our previous epi-
demiologic study enrolled preterm infants who have similar
birth weight and gestational age irrespective of whether tra-
cheal intubation was done or not in delivery room (3). This
difference supports the likelihood of a higher proportion of
antenatally adversely affected preterm infants in our present
study. Therefore, hasty generalization of our results should
not be made. 
In conclusion, positive correlation of TGF-β 1 mRNA expres-
sion in BAL cells obtained from preterm infants shortly after
birth with maturity and decreased expression of TGF-β 1m R N A
in the presence of maternal chorioamnionitis suggest a possi-
bility that maternal chorioamnionitis might inhibit the nor-
mal lung development of fetus. However, further studies will
be necessary to delineate the representativeness of non-bron-
choscopic BAL cells of alveolar environment and search for
better easily obtainable pulmonary specimens that have a
good reflection of alveolar environment in human preterm
infants.
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